The Europe Sciatica Treatment Market should witness market growth of 3.1% CAGR during the forecast period (2022-2028).
Sciatica produces tingling, numbness, and a burning feeling that radiates from the lower back and upper buttocks down the back of the hamstring to the back of the foot. Leg discomfort, hip pain, buttock pain, and lumbar pain are the effects of this. There are times when the discomfort extends around the hips or buttocks, feeling something comparable to a hip ache. Walking difficulties might result from severe sciatica.
Surgery is indicated if the discomfort lasts longer than three months. The underlying reasons for sciatica are therapy's main focus, leading to quicker pain alleviation and recovery. The therapy process makes little or no use of electromagnetic waves or medications. As a result, this kind of therapy has no adverse effects on the body. Stress and muscular trigger points are relieved during sciatica therapy. It may trigger the body's innate healing process all over. The patient may avoid spinal surgery as a result. Also, it significantly lessens muscular strains and ligament sprains.
In England, half of the individuals (or 63% of adults) who are overweight or obese will be living there by 2020. As they graduate from elementary school, one in three kids is already overweight or obese, and one in five of them do. The most disadvantaged segments of society have the greatest rates of obesity. According to comparable international figures on overweight and obesity from 2008 (1), 60.5% of adults in Germany (> 20 years old) were heavy, and 25.1% were obese. Men (66.8%) were more likely than women (54.5%) to be overweight. It is anticipated that the rising incidence of obesity and overweight would increase the risk of sciatica. The sciatica treatment market is expected to increase in Europe because of all these reasons.
The Germany market dominated the Europe Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $55,234.7 Thousands by 2028. The UK market is anticipated to grow a CAGR of 2.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022-2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Based on End-user, the market is segmented into Hospitals, Prosthetic Clinics, Rehabilitation Centers and Others. Based on Type, the market is segmented into Passive, Active and Hybrid. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Sciatica produces tingling, numbness, and a burning feeling that radiates from the lower back and upper buttocks down the back of the hamstring to the back of the foot. Leg discomfort, hip pain, buttock pain, and lumbar pain are the effects of this. There are times when the discomfort extends around the hips or buttocks, feeling something comparable to a hip ache. Walking difficulties might result from severe sciatica.
Surgery is indicated if the discomfort lasts longer than three months. The underlying reasons for sciatica are therapy's main focus, leading to quicker pain alleviation and recovery. The therapy process makes little or no use of electromagnetic waves or medications. As a result, this kind of therapy has no adverse effects on the body. Stress and muscular trigger points are relieved during sciatica therapy. It may trigger the body's innate healing process all over. The patient may avoid spinal surgery as a result. Also, it significantly lessens muscular strains and ligament sprains.
In England, half of the individuals (or 63% of adults) who are overweight or obese will be living there by 2020. As they graduate from elementary school, one in three kids is already overweight or obese, and one in five of them do. The most disadvantaged segments of society have the greatest rates of obesity. According to comparable international figures on overweight and obesity from 2008 (1), 60.5% of adults in Germany (> 20 years old) were heavy, and 25.1% were obese. Men (66.8%) were more likely than women (54.5%) to be overweight. It is anticipated that the rising incidence of obesity and overweight would increase the risk of sciatica. The sciatica treatment market is expected to increase in Europe because of all these reasons.
The Germany market dominated the Europe Sciatica Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $55,234.7 Thousands by 2028. The UK market is anticipated to grow a CAGR of 2.3% during (2022-2028). Additionally, The France market would exhibit a CAGR of 3.9% during (2022-2028).
Based on Type, the market is segmented into Chronic, Acute and Others. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies and Online Providers. Based on Drug Class, the market is segmented into Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Based on End-user, the market is segmented into Hospitals, Prosthetic Clinics, Rehabilitation Centers and Others. Based on Type, the market is segmented into Passive, Active and Hybrid. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Scope of the Study
By Type
- Chronic
- Acute
- Others
By Distribution Channel
- Retail & Specialty Pharmacies
- Hospital Pharmacies
- Online Providers
By Drug Class
- Non-Steroidal anti-inflammatory
- Steroids
- Antidepressants
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Sciatica Treatment Market, by Type
1.4.2 Europe Sciatica Treatment Market, by Distribution Channel
1.4.3 Europe Sciatica Treatment Market, by Drug Class
1.4.4 Europe Sciatica Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Sciatica Treatment Market by Type
3.1 Europe Chronic Market by Country
3.2 Europe Acute Market by Country
3.3 Europe Others Market by Country
Chapter 4. Europe Sciatica Treatment Market by Distribution Channel
4.1 Europe Retail & Specialty Pharmacies Market by Country
4.2 Europe Hospital Pharmacies Market by Country
4.3 Europe Online Providers Market by Country
Chapter 5. Europe Sciatica Treatment Market by Drug Class
5.1 Europe Non-Steroidal anti-inflammatory Market by Country
5.2 Europe Steroids Market by Country
5.3 Europe Antidepressants Market by Country
5.4 Europe Others Market by Country
Chapter 6. Europe Sciatica Treatment Market by Country
6.1 Germany Sciatica Treatment Market
6.1.1 Germany Sciatica Treatment Market by Type
6.1.2 Germany Sciatica Treatment Market by Distribution Channel
6.1.3 Germany Sciatica Treatment Market by Drug Class
6.2 UK Sciatica Treatment Market
6.2.1 UK Sciatica Treatment Market by Type
6.2.2 UK Sciatica Treatment Market by Distribution Channel
6.2.3 UK Sciatica Treatment Market by Drug Class
6.3 France Sciatica Treatment Market
6.3.1 France Sciatica Treatment Market by Type
6.3.2 France Sciatica Treatment Market by Distribution Channel
6.3.3 France Sciatica Treatment Market by Drug Class
6.4 Russia Sciatica Treatment Market
6.4.1 Russia Sciatica Treatment Market by Type
6.4.2 Russia Sciatica Treatment Market by Distribution Channel
6.4.3 Russia Sciatica Treatment Market by Drug Class
6.5 Spain Sciatica Treatment Market
6.5.1 Spain Sciatica Treatment Market by Type
6.5.2 Spain Sciatica Treatment Market by Distribution Channel
6.5.3 Spain Sciatica Treatment Market by Drug Class
6.6 Italy Sciatica Treatment Market
6.6.1 Italy Sciatica Treatment Market by Type
6.6.2 Italy Sciatica Treatment Market by Distribution Channel
6.6.3 Italy Sciatica Treatment Market by Drug Class
6.7 Rest of Europe Sciatica Treatment Market
6.7.1 Rest of Europe Sciatica Treatment Market by Type
6.7.2 Rest of Europe Sciatica Treatment Market by Distribution Channel
6.7.3 Rest of Europe Sciatica Treatment Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Johnson & Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expenses
7.5 Sorrento Therapeutics, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental Analysis
7.5.4 Research & Development Expenses
7.6 Alkem Laboratories Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Amneal Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental
7.7.4 Research & Development Expenses
7.8 Aurobindo Pharma Limited
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Novartis AG
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.10. Cadila Healthcare Ltd. (Zydus Cadila)
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Methodology
LOADING...
